SAB4700114
Monoclonal Anti-CD20 antibody produced in mouse
clone 2H7, purified immunoglobulin, buffered aqueous solution
Synonyme(s) :
Anti-MS4A1
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41
Produits recommandés
Source biologique
mouse
Niveau de qualité
Conjugué
unconjugated
Forme d'anticorps
purified immunoglobulin
Type de produit anticorps
primary antibodies
Clone
2H7, monoclonal
Forme
buffered aqueous solution
Espèces réactives
nonhuman primates, human
Concentration
1 mg/mL
Technique(s)
flow cytometry: 0.6 μg/mL
Isotype
IgG2b
Numéro d'accès NCBI
Numéro d'accès UniProt
Conditions d'expédition
wet ice
Température de stockage
2-8°C
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... MS4A1(931)
Description générale
CD20 is a cell surface 33-37 (depending on the degree of phosphorylation) kDa non-glycosylated surface phosphoprotein expressed on mature and most malignant B cells, but not stem cells or plasma cells (low number of the CD20 has been also detected on a subpopulation of T lymphocytes and it can be expressed on follicular dendritic cells). Its expression on B cells is synchronous with the expression of surface IgM. CD20 regulates transmembrane calcium conductance (probably functioning as a component of store-operated calcium channel), cell cycle progression and B-cell proliferation. It is associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change and/or BCR (B cell antigen receptor) aggregation. After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following mAb treatment.
The CD20 gene, mapped to human chromosome 11q12-13, codes for a B lymphocyte differentiation antigen. The protein encoded by the gene is a 33kDa transmembrane phosphoprotein, specifically expressed in normal and neoplastic B-cells. CD20, also known as MS4A1, is a member of membrane-spanning 4-domains subfamily A (MS4A) family of molecules with multiple membrane spanning domains.
Spécificité
The antibody 2H7 reacts with CD20 (Bp35), a 33-37 kDa non-glycosylated membrane receptor with four transmembrane domains, expressed on B lymphocytes (it is lost on plasma cells), follicular dendritic cells, and at low levels on peripheral blood T lymphocytes.
Immunogène
Human tonsillar B cells
Application
The reagent is designed for Flow Cytometry analysis. Suggested working dilution for Flow Cytometry is 0.6 μg/mL of sample. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.
Actions biochimiques/physiologiques
Restricted expression pattern of CD20 in B- cells helps in distinguishing B-cell from T-cell lymphomas. CD20, is considered to be a potential therapeutic target in the treatment of B-cell malignancies such as diffuse large B-cell lymphoma and chronic lymphocytic leukemia. CD20, might act as an ion channel, thereby permitting the influx of calcium essential for B cell activation, proliferation and differentiation. In humans CD20 deficiency, leads to impaired T cell–independent antibody responses. The monoclonal anti-CD20 antibody, Rituximab (RTX) reduces the increased CD20 expressing T cells in multiple sclerosis patients.
Caractéristiques et avantages
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Forme physique
Solution in phosphate buffered saline, pH 7.4, with 15 mM sodium azide.
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
10 - Combustible liquids
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
Katrin A Salva et al.
The American Journal of dermatopathology, 37(10), e116-e121 (2015-09-19)
Expression of the pan B-cell marker CD20 by T-cell lymphoproliferative disorders is exceedingly rare. We present a 52-year-old man with a unilesional cutaneous CD20 T-cell lymphoproliferative disorder. Multispectral imaging analysis of CD3-CD20 double-stained lesional tissue sections allowed (1) the visualization
Taco W Kuijpers et al.
The Journal of clinical investigation, 120(1), 214-222 (2009-12-30)
CD20 was the first B cell differentiation antigen identified, and CD20-specific mAbs are commonly used for the treatment of B cell malignancies and autoantibody-mediated autoimmune diseases. Despite this the role of CD20 in human B cell physiology has remained elusive.
T F Tedder et al.
Journal of immunology (Baltimore, Md. : 1950), 142(7), 2555-2559 (1989-04-01)
The human CD20 gene (B1) encodes a B lymphocyte-specific, cell-surface molecule that is involved in B cell activation and differentiation. We report that the CD20 gene is located on human chromosome 11 at position q12-q13. The location of CD20 was
Arumugam Palanichamy et al.
Journal of immunology (Baltimore, Md. : 1950), 193(2), 580-586 (2014-06-15)
In multiple sclerosis (MS), B cell-depleting therapy using monoclonal anti-CD20 Abs, including rituximab (RTX) and ocrelizumab, effectively reduces disease activity. Based on indirect evidence, it is generally believed that elimination of the Ag-presenting capabilities and Ag nonspecific immune functions of
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique